Ionis Pharmaceuticals (IONS) to Release Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is expected to be announcing its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of ($1.09) per share and revenue of $140.97 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Ionis Pharmaceuticals Price Performance

Shares of IONS opened at $31.58 on Wednesday. The firm has a market capitalization of $4.99 billion, a PE ratio of -12.94 and a beta of 0.34. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The company’s 50-day moving average is $34.62 and its 200-day moving average is $39.22. Ionis Pharmaceuticals has a fifty-two week low of $30.90 and a fifty-two week high of $52.34.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 33,445 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the transaction, the chief executive officer now owns 207,396 shares in the company, valued at approximately $6,767,331.48. This represents a 13.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Patrick R. O’neil sold 6,165 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total transaction of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares of the company’s stock, valued at $1,816,632.24. This represents a 9.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 110,609 shares of company stock worth $3,564,867 over the last ninety days. 2.71% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, January 15th. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Wells Fargo & Company lowered their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.